The University of Chicago Header Logo

Connection

J. Thistlethwaite to Cyclosporine

This is a "connection" page, showing publications J. Thistlethwaite has written about Cyclosporine.
Connection Strength

0.816
  1. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. Am J Kidney Dis. 1999 Jul; 34(1):69-84.
    View in: PubMed
    Score: 0.163
  2. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Jun; 30(4):1538-40.
    View in: PubMed
    Score: 0.152
  3. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation. Transplant Proc. 1998 Mar; 30(2):507-8.
    View in: PubMed
    Score: 0.149
  4. Evaluation of pre- and posttransplant donor-specific transfusion/cyclosporine A in non-HLA identical living donor kidney transplant recipients. Cooperative Clinical Trials in Transplantation Research Group. Transplantation. 1999 Oct 27; 68(8):1117-24.
    View in: PubMed
    Score: 0.042
  5. Liver transplantation in the first three months of life. Transplantation. 1998 Sep 15; 66(5):606-9.
    View in: PubMed
    Score: 0.039
  6. Successful use of tacrolimus for initial rejection episodes after liver transplantation. Transplant Proc. 1998 Jun; 30(4):1407-8.
    View in: PubMed
    Score: 0.038
  7. Cyclosporine versus cyclosporine microemulsion in pediatric liver transplant recipients. Transplant Proc. 1998 Jun; 30(4):1435-6.
    View in: PubMed
    Score: 0.038
  8. Reversal of accelerated renal allograft rejection with FK 506. Clin Transplant. 1997 Aug; 11(4):251-4.
    View in: PubMed
    Score: 0.036
  9. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation. Transplant Proc. 1996 Aug; 28(4):2136-7.
    View in: PubMed
    Score: 0.033
  10. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. Transplantation. 1996 May 15; 61(9):1365-9.
    View in: PubMed
    Score: 0.033
  11. OKT3 prophylaxis improves long-term renal graft survival in high-risk patients as compared to cyclosporine: combined results from the prospective, randomized Belgian and US studies. Transplant Proc. 1995 Feb; 27(1):852-3.
    View in: PubMed
    Score: 0.030
  12. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004 Oct 27; 78(8):1233-6.
    View in: PubMed
    Score: 0.015
  13. Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. Transplant Proc. 1998 Jun; 30(4):1234-5.
    View in: PubMed
    Score: 0.009
  14. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. J Pediatr. 1997 Jul; 131(1 Pt 1):98-104.
    View in: PubMed
    Score: 0.009
  15. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation. 1996 Sep 15; 62(5):594-9.
    View in: PubMed
    Score: 0.008
  16. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. Transplant Proc. 1996 Apr; 28(2):998-9.
    View in: PubMed
    Score: 0.008
  17. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int. 1996 Mar; 49(3):768-72.
    View in: PubMed
    Score: 0.008
  18. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation. 1993 Jan; 55(1):44-50.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.